引言：癌症免疫学特刊——免疫疗法。 - Suppr

Suppr

超能文献

Introduction: Cancer Immunology Special Issue-Immunotherapy.

作者信息

Kawakami Yutaka

机构信息

Guest Editor.

出版信息

Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.

DOI:10.1093/intimm/dxw028

PMID:27313100

Abstract

摘要

相似文献

Introduction: Cancer Immunology Special Issue-Immunotherapy.

Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.

The present status and future prospects of peptide-based cancer vaccines.

Int Immunol. 2016 Jul;28(7):319-28. doi: 10.1093/intimm/dxw027. Epub 2016 May 28.

STING signaling: a key to therapeutic tumor immunity.

Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064.

Coinhibitory Pathways in Immunotherapy for Cancer.

Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.

Part II: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(7):761-2. doi: 10.2217/imt-2014-0051.

The benefits of immunotherapy combinations.

Nature. 2017 Dec 21;552(7685):S67-S69. doi: 10.1038/d41586-017-08702-7.

Part I: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.

Novel Immunologic Approaches to Melanoma Treatment.

Actas Dermosifiliogr. 2017 Oct;108(8):708-720. doi: 10.1016/j.ad.2017.01.017. Epub 2017 May 18.

Hiding in Plain Sight: Soluble Immunomodulatory Receptors.

Trends Immunol. 2018 Oct;39(10):771-774. doi: 10.1016/j.it.2018.08.004. Epub 2018 Sep 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Introduction: Cancer Immunology Special Issue-Immunotherapy.

Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.

The present status and future prospects of peptide-based cancer vaccines.

Int Immunol. 2016 Jul;28(7):319-28. doi: 10.1093/intimm/dxw027. Epub 2016 May 28.

STING signaling: a key to therapeutic tumor immunity.

Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064.

Coinhibitory Pathways in Immunotherapy for Cancer.

Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.

Part II: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(7):761-2. doi: 10.2217/imt-2014-0051.

The benefits of immunotherapy combinations.

Nature. 2017 Dec 21;552(7685):S67-S69. doi: 10.1038/d41586-017-08702-7.

Part I: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.

Novel Immunologic Approaches to Melanoma Treatment.

Actas Dermosifiliogr. 2017 Oct;108(8):708-720. doi: 10.1016/j.ad.2017.01.017. Epub 2017 May 18.

Hiding in Plain Sight: Soluble Immunomodulatory Receptors.

Trends Immunol. 2018 Oct;39(10):771-774. doi: 10.1016/j.it.2018.08.004. Epub 2018 Sep 5.